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Abstract
Background: Immune cells within the tumor can act either to promote growth or rejection of tumor cells. The aim
of the present study was to evaluate immune cell markers (number and localization) within the tumor before and
during rejection due to radioimmunotherapy, to determine whether there is a change in markers related to
rejection and/or tolerance of the tumor cells.
Methods: Thirty immunocompetent rats were inoculated with syngeneic rat colon carcinoma cells and 13–14 days
later 21 of these rats were treated with 400 MBq/kg of 177Lu-DOTA-BR96 monoclonal antibodies. The treated
animals were sacrificed and dissected 1, 2, 3, 4, 6, and 8 days post-injection in groups of three animals per day
(6 animals on day 8); while the nine untreated animals were sacrificed and dissected on day 0. Paraffin sections
were used for immunohistochemical staining of CD2, CD3, CD8α, CD68, and CD163 antigens. Positive cells were
counted within: vital tumor cell areas, necrotic areas, granulation tissue surrounding and between the tumor cell
areas. The change in the number of positive cells over time in tumors treated with radioimmunotherapy in the same
location was evaluated with linear regression models. The number of positive cells in various locations and the number
of various antigen-positive cells within the same location were also evaluated over time using box plots.
Results: There were a higher number of cells expressing immune cell markers in granulation tissue compared with
vital tumor cell areas. Cells expressing markers decreased during radioimmunotherapy, and T-cell markers decreased
more than macrophage markers in tumors treated with radioimmunotherapy. The expression of CD8α was higher than
that of the other T-cell markers evaluated (CD3 and CD2), which could be explained by the additional expression of
CD8α by natural killer (NK) cells and a subset of dendritic cells (DCs). The expression of CD68 (all macrophages, DCs,
and neutrophils) tended to be higher than that of CD163 (pro-tumor macrophages).
Conclusions: In this model, we demonstrated a higher number of positive cells for immune cell markers related to
augmenting the immune rejection than immune tolerance of tumor cells in tumors and a decrease in markers
during radioimmunotherapy.
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Background
Distant metastases are the main reason that patients die
from cancer [1]. It is thus important to identify patients
with a high risk of developing metastases and try to pre-
vent the development of tumor cells into metastases,
since metastases can develop after years of undetectable
disease. This has been explained by escape from dormancy
using, for example, immunosurveillance [2–6]. This
means that tumor cells are present but do not evolve into
a detectable tumor due to the action of the immune sys-
tem. If the immune response fails to suppress the growth
of tumor cells, they will evolve into a detectable tumor. It
would be informative to evaluate the infiltration of im-
mune cells in the primary tumor [7–11], since it has been
shown that immunoscore classification of tumors is a clin-
ically useful prognostic factor [12, 13]. Immunotherapeu-
tic strategies aiming to overcome the immune tolerance of
tumor cells are a new promising approach. An example of
this is the use of an immune checkpoint inhibitor (e.g., ipi-
limumab) directed against the cytotoxic T lymphocyte
antigen (CTLA-4), which has been found to improve the
survival of patients with metastatic melanoma [14–16].
Our rat colon carcinoma model is syngeneic, as the
cell line used was established in the same rat strain as
used in the experiments. The animals are fully immuno-
competent making the model more clinically relevant. In
a previous study on this immunocompetent syngeneic rat
colon carcinoma model, we demonstrated that treatment
with 177Lu-labeled monoclonal antibodies (radioimmu-
notherapy, RIT) resulted in local complete response (CR)
in the majority of the animals (17 of 19) within 2 weeks
[17]. However, half of the animals developed distant me-
tastases during the follow-up period of 100 days post-
injection (p.i.).
The therapeutic effect of RIT is derived from both the
antibody and the decay of the radionuclide (in this case
177Lu). To the best of our knowledge, no studies have
been carried out to evaluate the effects of RIT on the in-
filtration of immune cells into tumors. The aim of the
present study was, thus, to evaluate immune cell markers
(both number and localization) within the local tumor at
the time of treatment and during rejection due to RIT,
in order to determine whether there is any change in
the markers related to rejection and/or tolerance of the
tumor cells.
Methods
The syngeneic animal model
BN7005-H1D2 is a cell line established from a 1,2-di-
methylhydrazine-induced colon carcinoma in a Brown
Norway (BN) rat [18]. We determined the radiosensitiv-
ity of this cell line, expressed as the fraction of survival
after 2 Gy to be 0.5 (137Cs radiation source, unpublished
data). This is similar to the radiosensitivity of human
colorectal carcinoma cell lines [19]. The cells were cul-
tured in RPMI-1640 medium supplemented with 10 %
fetal calf serum (both from PAA Laboratories GmbH,
Pasching, Austria), 1 mM sodium pyruvate, 10 mM
HEPES buffer, and 14 mg/L gentamicin (all from Gibco,
Invitrogen, Carlsbad, CA) at 37 °C, in a humidified en-
vironment containing 5 % CO2. The cells were washed
in PBS and detached by treatment with trypsin (both
from PAA Laboratories GmbH).
BN rats are immunocompetent and express the target
antigen (Lewis Y, Ley) in normal tissues, mainly in the
epithelium of the gastrointestinal tract [20], similar to
humans [21]. The animals were inoculated with 3 × 105
cells between the peritoneum and the abdominal wall
under general anesthesia (isoflurane, Abbott Scandinavia
AB, Solna, Sweden). Tumor volumes were calculated as
tumor length × tumor width2 × 0.4 [22]. All experiments
were conducted in compliance with European legislation
on animal welfare and were approved by the Regional
Animal Ethics Committee (Malmö/Lunds djurförsöksetiska
nämnd). The animals were housed under standard con-
ditions and fed with standard pellets and fresh water ad
libitum.
The radioimmunoconjugate
The chimeric (mouse/human) monoclonal IgG1 antibody
BR96 (Seattle Genetics Inc., Seattle, WA) binding to the
Ley was employed. The tumor-associated antigen Ley is
expressed on the majority of human epithelial tumors.
The dissociation constant between BR96 and the cell line
used is 4 nM [23], illustrating its strong binding affinity.
Conjugation of BR96 and DOTA was performed ac-
cording to Forrer et al. [24]. Briefly, BR96 was trans-
ferred to 0.2 M sodium carbonate buffer, pH 9.5, by
repeated centrifugation using an Amicon Ultra-15 filter
(MW 30 000, Millipore, Billerica, MA). All empty vials
were pretreated with 1 % HNO3 and all buffers were
pretreated with Chelex-100 (BioRad, Hercules, CA) to
remove metals. The DOTA chelate (S-2-(4-isothiocyana-
tobenzyl)-1, 4, 7, 10-tetraazacyclododecane tetraacetic
acid; Macrocyclics, Dallas, TX, 2 mg/mL H2O) was
added to the BR96 antibody (100 mg/mL) at a molar ra-
tio of 3:1 (DOTA:BR96) and incubated for 1 h at 37 °C.
The conjugate was purified by repeated centrifugation
using an Amicon Ultra-15 filter and transferred to
0.25 M ammonium acetate buffer, pH 5.3, and the final
concentration was adjusted to 10 mg/mL BR96.
MALDI-MS was used to determine the number of
DOTA moieties per BR96 molecule, by desalting the
sample to 18 MΩ · cm H2O using a centrifugation filter
device, and dividing the increase in molecular mass by
688 (the molecular mass of the DOTA chelate).
The immunoreactivity (i.e. the antigen-binding proper-
ties) of DOTA-BR96 relative to BR96 was determined
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from a saturation binding curve, using BN7005 cells as
the target antigen. Briefly, increasing concentrations of
BR96 and DOTA-BR96 (40 μg/mL–40 mg/mL) were
added to the cell plate in triplicate and incubated for at
least 90 min. The bound BR96/DOTA-BR96 conjugates
were detected with rabbit anti-human IgG-HRP (Dako,
Glostrup, Denmark), and the equilibrium binding constant
(Kd) was calculated using Prism 5.02 software (GraphPad
Software Inc., binding saturation-one site total, non-
specific binding and background constrained to a constant
value of zero). The immunoreactivity was given by the ra-
tio of the binding constants: Kd(BR96)/Kd(DOTA-BR96).
Both the DOTA-BR96 conjugate in 0.25 M ammonium
acetate buffer and the 177LuCl3 solution (MDS Nordion,
Vancouver, Canada) were preheated to 45 °C for 10 min.
The DOTA-BR96 solution was then added to the vial con-
taining the radionuclide and incubated at 45 °C for 15 min.
The reaction was quenched with excess DTPA (diethylene
triamine pentaacetic acid) for 5 min. The radiolabeled
immunoconjugate was diluted in 1 % human serum
albumin (HSA, Baxter Medical AB, Kista, Sweden) to pre-
vent radiolysis from affecting the immunoreactivity. The
radiochemical purity was determined with instant thin-
layer chromatography (ITLC) using a 1 × 9 cm silica-gel-
impregnated fiberglass sheet as the solid phase and 0.1 M
EDTA as the mobile phase. To analyze the radiochemical
purity and to detect signs of aggregation or fragmentation,
separation was performed using size-exclusion chroma-
tography and high-performance liquid chromatography
(HPLC) (using a 7.8 × 300 mm molecular sieving column,
Phenomenex SEC S3000; Phenomenex, Torrance, CA,
eluted with 0.05 M sodium phosphate at 1.0 mL/min).
Radioimmunotherapy with 177Lu-DOTA-BR96
Thirty male BN rats (Harlan, Horst, the Netherlands) were
included in the study. Their median weight on the day of
administration of RIT (day 0) was 238 g. Twenty-one rats
were treated with 400 MBq/kg body weight of 177Lu-
DOTA-BR96 (150 μg DOTA-BR96 in 0.4-mL saline with
1 % HSA) by intravenous injection in the tail vein 13–
14 days after cell inoculation. Our previous study showed
that 400 MBq/kg body weight resulted in CR in 17 of 19
animals [17], and that the maximum tolerable activity was
600 MBq/kg body weight [25]. The nine remaining ani-
mals were left untreated as a control group. The treated
animals were sacrificed and dissected 1, 2, 3, 4, 6, and
8 days p.i. in groups of three animals per day (6 animals
on day 8), while the untreated animals were sacrificed and
dissected on day 0. The tumors were cut in half, fixed in
4 % paraformaldehyde, and embedded in paraffin.
Immunohistochemistry
Consecutive 4 μm paraffin sections were used to detect
CD2, CD3, CD8α, CD68, and CD163. The characteristics
of the antibodies and antigens stained are presented
in Table 1. Note that all macrophages express CD68,
while CD163 is only expressed by M2 (pro-tumor macro-
phages) [26, 27].
Sections were rehydrated and antigen retrieval was
performed using the PT Link pre-treatment (Dako) with
Target Retrieval Solution, pH 6 (Dako), preheated to 65 °C.
The sections were then heated to 99 °C for 20 min and
allowed to cool at room temperature for at least 1 h. The
slides were rinsed with distilled water, and endogenous
peroxidase was blocked by Peroxidase-Blocking Solution,
endogenous biotin by Biotin Blocking System, and pro-
teins by Protein Block Serum-Free (all from Dako). The
sections were incubated for 1 (CD2 and CD163) or 1.5 h
(CD3, CD8α, and CD68) at room temperature with pri-
mary antibody. After washing with Wash Buffer (Dako),
the primary antibodies were detected with LSAB2 System-
HRP for use on rat specimens (Dako) according to the
manufacturer’s instructions. Finally, Liquid DAB+ Sub-
strate Chromogen System (Dako) was used to visualize
the antigens before counterstaining with hematoxylin and
mounting with Pertex (Histolab, Goteborg, Sweden).
Evaluation of immunohistochemistry sections
All sections were evaluated blindly by an experienced
clinical pathologist (OL). Positive cells were counted in:
vital tumor cell areas, necrotic areas, granulation tissue
surrounding the tumor cell areas, and between tumor
cell areas. The number of positive cells within the high-
power field of view of 40× (0.24 mm2) was evaluated in
two hot spots selected to contain evenly distributed
positive cells within the field of view. In views with more
than 100 positive cells, the number of positive cells
along a diameter of the view was counted. The diameter
was chosen randomly. The total number (n) of positive
Table 1 Antibody characteristics and antigen expression
Antigen Clone (supplier) Dilution Antigen expression on tumor-infiltrating cells
CD2 OX-35 (AbD Serotec) 1:800 T-cells, B-cells, NK cells
CD3 Polyclonal (18–0102, Invitrogen) 1:200 T-cells
CD8α OX-8 (AbD Serotec) 1:200 Cytotoxic T-cell, NK cells, DC subset
CD68 ED-1 (AbD Serotec) 1:200 All macrophages, neutrophils, DC, myeloid progenitors (e.g. myeloid-derived suppressor cell)
CD163 ED-2 (LSBio, LifeSpan BioSciences) 1:200 Pro-tumor macrophages (M2) [26, 27]
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cells within the field of view was then calculated using
the following equation:




The calculated number of positive cells was confirmed
by manual counting in three fields of view, and the
calculated value correlated very well with the manually
counted values (data not shown).
In some cases, the areas were located in a band-like
distribution (mainly granulation tissue) and the areas
were not always large enough to cover the whole micro-
scopic field of view. In such instances, the field was ori-
ented in such a way that the area was adjusted to
include the diameter of the field of view. The number of
positive cells was counted along the diameter and the
total number of positive cells was calculated as described
above. This procedure was considered necessary to be
able to compare density of positive cells over time, be-
tween different locations and different immune cell
markers.
Statistics
The change in the number of antigen-positive cells was
evaluated using simple linear regression of the log count
over time. All immune cell markers (CD2, CD3, CD8α,
CD68, and CD163) were individually evaluated in the
following locations: vital tumor cell areas, granulation
tissue surrounding the tumor cell areas and between
tumor cell areas. Multiple linear regression models,
including tumor volume on day 0 or tumor volume on
the day of sacrifice, were used to evaluate the extent to
which the time trends were confounded by tumor vol-
ume. Although the linear regression models for the dif-
ferent markers and locations did not always show a good
fit to the observed data, they still provided an estimate
of trends over time. However, the corresponding regres-
sion coefficients should be interpreted as average effects
over the follow-up period.
Box plots of ratios of different locations (granulation
tissue surrounding the tumor cell areas and between
tumor cell areas vs vital tumor cell areas), stratified by
time interval, were used to visually compare the number
of antigen-positive cells for each antigen. The same tech-
nique was use to compare the number of positive cells
of different antigens within the same location. Null
hypotheses of no difference (ratio 1.0) were evaluated
separately for each time interval using the Wilcoxon
matched-pairs signed rank sum test.
Animals with no tumor (CR) at the time of sacrifice
on days 4 and 6 were not included in the analyses. The
scar tissue from tumors on day 8 was collected but
could not be included in the calculations since they
lacked tumor cell areas.
All statistical calculations were performed using Stata
13.1 (StataCorp LP, College Station, TX).
Results
The radioimmunoconjugate
The average number of DOTA molecules conjugated per
BR96 antibody was 2.4. The immunoreactivity was 0.9,
indicating that the antigen-binding properties did not
change as a result of conjugation with DOTA. The radio-
chemical purity of 177Lu-DOTA-BR96 was analyzed using
ITLC and found to be 97 %, and less than 1 % of the activ-
ity was found in aggregates according to HPLC.
Tumor sampling
All 30 rats developed local tumors between the periton-
eum and the abdominal wall before the day of treat-
ment (day 0). The median tumor volume on day 0 was
1140 mm3 (interquartile range 900–1580 mm3). The nine
untreated control animals were sacrificed, and the tumors
were excised on day 0. The animals treated with RIT were
sacrificed and the local tumor was excised 1, 2, 3, 4, 6, or
8 days p.i. in groups of 3 rats per day, apart from day 8 p.i.
when 6 rats were sacrificed. Tumor tissues could not be
sampled in 5 rats due to CR: on day 4 (1 CR), day 6 (1
CR), and day 8 (3 CR) p.i. Scar tissue from tumors
was collected from rats showing CR on day 8 p.i.
T-cell markers—CD2, CD3, and CD8α
All T-cell markers decreased in tumors treated with RIT
compared with untreated tumors in all areas evaluated,
although this was not statistically significant in all cases,
see Table 2 and Fig. 1. The potential confounding effect
of tumor volume (day 0 or at sacrifice) was evaluated
using multiple linear regression, and the estimated time
trends were essentially the same as without adjustment
for tumor volume (data not shown). The T-cell markers
were not expressed in necrotic areas, thus necrotic areas
were not included in the following analysis.
All T-cell markers had more positive cells in the
granulation tissue (both surrounding and between tumor
cell areas) than in the vital tumor cell areas (Fig. 2a–c
and Table 2). There were a higher number of positive
cells for CD8α than CD2 and CD3 and a tendency
towards more positive cells for CD2 than CD3 both in
untreated tumors and treated tumors.
Macrophage markers—CD68 and CD163
The number of positive cells for both macrophage
markers decreased less than T-cell markers in tumors
treated with RIT, compared with untreated tumors in all
the areas evaluated, see Table 2 and Fig. 3. The potential
confounding effect of tumor volume (day 0 or at sacrifice)
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Table 2 Statistical evaluation of the change in immune cell marker positive cells after administration of RIT. The number of antigen-
positive cells at day 0 and the average change in positive cells within tumors treated with RIT (% per day, confidence interval and
p value) at different localizations
Antigen Localization Positive cells on day 0
median (range)
Average change after admin.
of radioimmunoconjugate
(95 % confidence interval)
p value
CD2 Tumor cell areas 20 (0–80) −30 % per day (−48 to −5.5) 0.022
Granulation tissue between tumor cell areas 240 (110–450) −33 % per day (−51 to −8.2) 0.015
Granulation tissue surrounding tumor cell areas 370 (110–370) −36 % per day (−52 to −15) 0.003
CD3 Tumor cell areas 50 (0–150) −36 % per day (−49 to −18) 0.001
Granulation tissue between tumor cell areas 350 (150–570) −24 % per day (−30 to +17) <0.001
Granulation tissue surrounding tumor cell areas 480 (130–910) −29 % per day (−36 to −20) <0.001
CD8α Tumor cell areas 90 (30–180) −10 % per day (−29 to +13) 0.35
Granulation tissue between tumor cell areas 260 (80–490) −0.1 % per day (−4.4 to +4.9) 0.95
Granulation tissue surrounding tumor cell areas 340 (180–530) −4.7 % per day (−8.8 to +0.41) 0.033
CD68 Tumor cell areas 310 (130–640) −1.3 per day (−11 to +9.7) 0.80
Granulation tissue between tumor cell areas 510 (310–710) +1.1 % per day (−2.8 to +5.3) 0.56
Granulation tissue surrounding tumor cell areas 560 (200–910) −9.7 % per day (−14 to −5.1) <0.001
CD163 Tumor cell areas 160 (60–380) −13 % per day (−26 to +0.47) 0.057
Granulation tissue between tumor cell areas 190 (110–310) +1.1 % per day (−2.8 to +5.3) 0.56
Granulation tissue surrounding tumor cell areas 200 (100–380) −4.2 % per day (−9.7 to +1.5) 0.14
Fig. 1 Images of immunohistochemical sections after staining of T-cell markers. CD2 (T-cells, B-cells, NK cells), CD3 (T-cells), CD8α (cytotoxic
T-cells, NK cells, DC subset) in sequential sections of paraffin-embedded tumors. The brown staining illustrates the immune cell markers and the
blue staining illustrates the cell nuclei. All images show both granulation tissue (filled arrowhead) and tumor cell area (arrowhead). left: untreated
tumors, right: tumor 3 days after administration of radioimmunoconjugate. Note that the decrease of CD8α-positive cells during this interval is less
than that of CD2 and CD3. Scale bars: 100 μm
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Fig. 2 (See legend on next page.)
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was evaluated using multiple linear regression, and the
estimated time trends were essentially the same as without
adjustment for tumor volume (data not shown). The
macrophage markers were only expressed as fragments
and had no vital cell association in necrotic areas and nec-
rotic areas were not included in the following analysis.
Both macrophage markers tended to have more posi-
tive cells in the granulation tissue (both surrounding and
between vital tumor cell areas) than in the vital tumor
cell areas (Fig. 2g–h and Table 2). There were a higher
number of positive cells for CD68 than CD163 both in
untreated tumors and treated tumors.
Discussion
We have demonstrated that the model used in this study
has a higher number of positive cells of immune cell
markers augmenting immune rejection of tumor cells
than immune tolerance of tumor cells, i.e. a higher num-
ber of positive cells for CD8α than CD2 and CD3 and a
higher number of positive cells for CD68 than CD163.
The infiltrating immune cells seem to be present to a
higher extent in untreated tumors than in tumors
treated with RIT. The histological features of untreated
tumors and tumors from animals treated with RIT have
been described previously, showing that the fraction of
granulation tissue increased in tumors treated with RIT
(maximum at 4 days p.i.), and that the granulation tissue
matured into fibrous tissue which increased throughout
the study period [28].
All the immune cell markers were found to have a
higher number of positive cells in the granulation tissue
than within the vital tumor cell areas. CD8α (antitumor
immune cells) decreased less in tumors treated with RIT
than the other T-cell markers (CD2 and CD3). The
macrophage markers evaluated (CD68 and CD163) de-
creased less in tumors treated with RIT than the T-cell
markers. There was a trend towards a higher number of
positive cells for CD68 than CD163 (pro-tumor macro-
phages) in tumors both before and after the administra-
tion of 177Lu-BR96.
The observation that the immune cell marker positive
cells tended to decrease within the tumors treated with
RIT could be explained by the continuous decay of 177Lu
in the tumor. Lymphocytes are radiosensitive to low
doses of radiation [29–31], while macrophages, natural
killer (NK) cells, and dendritic cells (DC) are more
resistant to irradiation [29, 30]. This could explain why
the decrease in CD3 (T-cells) and CD2 (T-cells, B-cells,
Fig. 3 Images of immunohistochemical sections after staining of macrophage markers. CD68 (macrophages, neutrophils, DC, myeloid progenitors,
e.g., myeloid suppressor cell) and CD163 (M2, macrophages of pro-tumor type [26, 27]) in sequential sections of paraffin-embedded tumors. The
brown staining illustrates the immune cell markers and the blue staining illustrates the cell nuclei. All images show both granulation tissue (filled
arrowhead) and tumor cell area (arrowhead). left: untreated tumors, right: tumor 3 days after administration of radioimmunoconjugate. Note the
higher number of positive cells for CD68 during this interval than that of CD163. Scale bars: 100 μm
(See figure on previous page.)
Fig. 2 Antigen expression over time. Number of positive cells for the immune cell markers expressed as ratios of expression in tumor cell areas/
granulation area between the tumor cell areas (granulation tissue) over time (box plots, stratified by time interval) in tumors treated with RIT
(a–c; g–h). Number of positive cells for various immune cell marker ratios within the tumor cell areas over time in tumors treated with RIT (d–f; i).
A ratio of 1.0 indicates no difference. No box is shown for day 6–8 in F as only two data points were available
Elgström et al. EJNMMI Research  (2015) 5:47 Page 7 of 9
NK cells) was more pronounced than that of CD8α
(cytotoxic T-cells, NK cells, subset of DC), CD68 (mac-
rophages, neutrophils, DC, myeloid progenitors), and
CD163 (pro-tumor macrophages, M2).
One advantage of immunohistochemical staining is that
it provides information on the localization of the antigens
within the structures of the tumor. Others have shown
that the localization of immune cell markers is an import-
ant predictor of clinical outcome [7, 8, 11, 12, 26, 32–34].
Deschoolmeester et al. showed that a high infiltrating
CD3- and CD8-positive cells in cancer cell nests was cor-
related to improved overall survival in colorectal cancer
[8]. Pagès et al. suggested an immunological score based
on the quantification of CD3, CD45RO, and CD8 in the
core of the tumor and in the invasive margin within the
tumor samples. This score was found to be a better
predictor of patient survival than the histopatho-
logical methods currently used to stage colorectal cancer
[11, 12, 33].
The results of immunohistochemical examinations
cannot be related directly to cell type, mainly due to the
expression of immune cell markers on more than one
cell type. The immune cell markers used in the present
study and their expression on various immune cells are
summarized in Table 1. In the present study, T-cells
stained positive for both anti-CD3 and anti-CD2, but
CD2 is also expressed by NK and B-cells. CD8α is
expressed by cytotoxic T-cells (which also express CD2
and CD3) and NK cells, and a subset of DC. The CD68
antigen is expressed by all macrophages, neutrophils,
basophils, DC, and myeloid progenitor cells (e.g., myeloid-
derived suppressor cell), while CD163 is expressed by M2
(pro-tumor macrophages) [26, 27].
The therapeutic effect of external irradiation on dis-
tant non-irradiated tumor cells (the abscopal effect) has
been shown to be at least partly due to the induction of
the immune response [29, 31, 35–41]. However, both
the radiation dose and the delivery schedule seem to
be important for the induction of the abscopal effect
[31, 35, 37, 38, 40–43]. It has been demonstrated that
these factors can affect the infiltration of CD8α-positive
T-cells in tumors [29, 35, 38, 40, 43] and affect the type of
the macrophage response (pro-tumor, M2, or anti-tumor,
M1) [35, 40, 42, 44]. In a recent study, we demonstrated
that early depletion of CD8-positive cells in our rat model
treated with RIT seemed not to affect the rejection of the
inoculated tumor but increased the number of animals de-
veloping metastases [45]. This finding provides evidence
that the presence of CD8-positive cells is important in
preventing or delaying the development of metastases in
this model.
It is of therapeutic interest to evaluate the mechanisms
activating the immune system, and to the best of our
knowledge this is the first study to evaluate the
infiltration of immune cells in tumors after the adminis-
tration of a radioimmunoconjugate. In future studies, we
intend to investigate the effects of combining RIT and
immunotherapy in our immunocompetent syngeneic rat
tumor model.
Conclusions
Analysis of the number and localization of immune cell
markers within a local tumor at the time of treatment
and during rejection after administration of 177Lu-BR96
antibodies revealed that all the immune cell markers had
a higher number of positive cells in adjacent granulation
tissue than in tumor cell areas, and that positive cells for
T-cell markers decreased more than positive cells for
macrophage markers in tumors treated with RIT. We
have thus demonstrated that RIT in this model induce
both a shift in the balance to a higher number of cells
expressing immune cell markers related to immune rejec-
tion than markers related to immune tolerance of tumor
cells and also a decrease in cells expressing immune cell
markers during RIT compared with untreated tumors.
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